TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject will be between 18 to 80 years of age.~2. Subject has not been on Gralise.~3. Subject has not been on gabapentin for at least one month.~4. Subject agrees to make no change in his/her current pain medications during the study period to ensure that comparisons can be made before and after the Gralise treatment.~5. Subject has a VAS pain score of 5 or above at the beginning of the study.~6. Subject has had CRPS I for at least three months to avoid clinical uncertainty and minimize the study variation.~7. Female subjects of childbearing age must have a negative urine pregnancy test at the initial visit.~Exclusion Criteria:~1. Subject has severe liver or renal disease that will affect the elimination of Gralise. (Renal dysfunction is defined as eGFR \< 60. Hepatic dysfunction is defined as LFTs ≥ 3X ULN.)~2. Subject has pending litigation related to his/her CRPS I condition.~3. Subject is pregnant or lactating.~4. Subject is allergic to gabapentin or Gralise.~5. Subject has a positive urine (illicit) drug test.~6. Subject has any history of suicidal thoughts or behaviors, as self reported or in documented medical history.~7. Subjects with known seizure disorders (except febrile seizures) and/or taking antiepileptic drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CRPS I Pain Subjects (Type: EXPERIMENTAL): This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.~Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant, non-lactating females 18 years or older with a BMI of 18-40 kg/m2 inclusive.~* Regarding renal function, subjects will be classified as either normal or as suffering from mild,moderate or severe renal impairment. Classification of renal impairment will be estimated by the MDRD and Cockcroft-Gault formulae~Exclusion Criteria:~* Any disease, condition and/or chronic medications which might compromise the hematologic, cardiovascular, pulmonary renal, gastrointestinal, hepatic, or central nervous system; or other conditions that might interfere with the distribution, metabolism or excretion of study drug, or would place the subject at increased risk~* Evidence of significant respiratory, gastrointestinal or hepatic disease at screening~* Positive screen for hepatitis B surface antigen, or HIV~* Positive test in drugs of abuse screens or alcohol on admission to the clinic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Subjects with mild renal impairment (Type: EXPERIMENTAL): None
- Subjects with moderate renal impairment (Type: EXPERIMENTAL): None
- Subjects with normal renal function (Type: EXPERIMENTAL): None
- Subjects with severe renal impairment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Blue Light Therapy for Liver Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age greater than 17 years~* undergoing right or left hepatic lobectomy~Exclusion Criteria:~* presence of acute traumatic brain injury~* blindness~* immunosuppression or immunocompromised condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Blue light (Type: EXPERIMENTAL): Subjects will be exposed to 24 hours of bright (1700 lux) blue (peak 442 nm) spectrum light the day prior to operative intervention and for the 24 hours after the operative intervention.
- Ambient light (Type: NO_INTERVENTION): Subjects will be exposed preoperatively to the lighting conditions of their living environment and postoperatively to the standard, white fluorescent lighting environment of the hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria as per the product label for LA SCCHN approved by India Health Authority~* Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck~* Patient willing and able to give written Informed Consent~* Patient capable of complying with study data collection procedures~Exclusion Criteria:~* Exclusion criteria as per the product label for LA SCCHN approved by India Health Authority

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients planned to undergo osteosynthesis with short intramedullary nail for a pertrochanteric hip fracture.~* ASA score 3, 2 or 1~Exclusion Criteria:~* Allergy for tranexamic acid~* Clinical signs of acute thromboembolic event~* Renal function impairment (S-creatinin\>120micromol/l)~* Active thrombotic disease or DIC~* K-vitamin antagonist treatment~* Malignancy~* Pathological fracture~* Previously operated in same hip~* BW \> 100kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients are given saline instead of tranexamic acid in the placebo group
- Tranexamic Acid (Type: ACTIVE_COMPARATOR): Tranexamic acid; 1 gram as a bolus prior to surgery. 3 grams of Tranexamic acid in 1 liter of saline as a 24 hour infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing PLA to HIGRT (PROVE-HCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCC diagnosed either by histology/pathology or Liver Imaging Reporting and Data System (LIRADs 5 per the ACR's LIRADs criteria) by CT or MRI~* Patient is 18 years or older~* ECOG Performance status of 0-2~* Child Pugh score A5, A6, B7 or B8~* Lesions less than or equal to 5cm in size~* Less than or equal to 3 lesions in the liver to be treated on protocol~* Lesion amenable to treatment with both PLA and HIGRT; for PLA treatment this requires the lesion be visible via ultrasound and/or non-contrast CT or feasible per treating physician~Exclusion Criteria:~* Child Pugh score B9 or Class C~* Fluctuating ascites~* Inability to complete baseline QOL forms~* Concurrent administration of systemic therapy for HCC~* Prior liver RT is an exclusion unless subject participation is approved by the PI~* Positive serum pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Percutaneous Local Ablation (PLA) (Type: ACTIVE_COMPARATOR): A PLA procedure uses high-energy radio waves to treat liver tumors. Using CT and ultrasound guidance the doctor inserts a thin, needle-like probe into the liver tumor A high-frequency current is then passed through the tip of the probe, which heats the tumor with the goal to destroy the cancer cells. This may be done as an outpatient procedure or a short (1-2 day) hospital stay. PLA is the standard treatment for patients with liver cancer who cannot undergo liver surgery.
- Hypofractionated Image-Guided Radiation Therapy (HIGRT) (Type: ACTIVE_COMPARATOR): HIGRT is an emerging treatment option for patients with HCC; it utilizes external radiation where multiple beams enter the body from multiple angles to treat the liver cancer over typically 5-10 treatments while minimizing radiation to normal tissues. You will receive between 5-10 fractions (treatments) of radiation. Fraction size will be either 5 or 10 Gy (pronounced Gray, a standard unit of radiation measurement) depending on your tumor size and location or underlying liver function. The total dose of radiation is 50 Gy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have a clinical diagnosis of schizophrenia for at least 1 year prior to screening~* Had been receiving treatment with antipsychotics, but is judged to be a candidate for changing antipsychotic on the basis of either persistent symptoms or continuing side effects~* Treating physician has determined, before the patient enters the study, that starting paliperidone extended release (ER) or another of at least two possible atypical antipsychotics (AAPs) is an appropriate treatment for the patient~* Likely to be managed as outpatient~* Must have signed the informed consent form for DNA pharmacogenomic~Exclusion Criteria:~* Have mental retardation, dementia, bipolar, schizoaffective disorder, schizophreniform disease, other Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) psychiatric disorders or deteriorating neurological illnesses as determined by clinical evaluation~* Established treatment-resistant schizophrenia, defined as those who have had treatment failures with adequate trials of two second generation atypicals, previous treatment with clozapine, or 4 or more hospitalizations in the last 12 months~* History of recent violence or at immediate risk of suicide, or harming self or others, or of causing damage to property, in the judgment of the investigator~* Patients who are unable to swallow the medication whole~* History or circumstances that may increase the risk of occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including bradycardia, hypokalemia or hypomagnesemia, concomitant use of drugs that prolong the QTc interval, or presence of congenital long QT syndrome~* Pregnant (as confirmed by urine pregnancy test performed at baseline), planning to become pregnant, or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paliperidone extended release (ER) (Type: None): Drug: Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
- Atypical antipsychotics agent (AAP) (Type: None): AAP includes quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates and infants, expected to require parenteral nutrition (PN) for 28 days~* Postmenstrual age ≥ 24 weeks~* Birth weight ≥ 750g~* Gastroschisis, duodenal, jejunal or ileal atresia, volvulus, spontaneous intestinal perforation or necrotizing enterocolitis (Bell's stage 2B or higher)~* At least 80% of nutritional needs at baseline received by PN~* Signed and dated informed consent obtained from at least one parent or legal guardian~Exclusion Criteria:~* Conjugated bilirubin \> 0.6 mg/dL~* Any known pre-, intra- or posthepatic complication increasing conjugated bilirubin levels \> 0.6, mg/dL during study participation~* Suspected liver disease or liver damage based on either aspartate aminotransferase (AST), alanine aminotransferase (ALT), or gamma-glutamyl transferase (GGT) exceeding 2.5x upper limit of normal range~* Active bloodstream infection demonstrated by positive blood culture at screening~* Cystic fibrosis~* Meconium ileus~* Serum triglyceride levels \> 250 mg/dL~* Cyanotic congenital heart defect~* Severe renal failure with serum creatinine \> 2.0 mg/dL~* History of shock requiring vasopressors~* Anasarca~* Extracorporeal Membrane Oxygenation (ECMO)~* Known inborn errors of metabolism~* Known congenital viral infection~* Unlikely to survive longer than 28 days~* Known hypersensitivity to fish-, egg-, soya- or peanut protein or to any of the active substances or excipients

- Gender: ALL
- Minimum Age: 0 Weeks
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Smoflipid 20% (Type: EXPERIMENTAL): Smoflipid is a lipid emulsion containing soybean oil, MCTs (medium-chain triglycerides), olive oil, and fish oil. Smoflipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions.
- Intralipid® 20% (Type: ACTIVE_COMPARATOR): Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologic/cytologic diagnosis of exocrine pancreas tumour~* resectable or borderline resectable exocrine pancreatic tumour (according to operability criteria)~* no metastasis from US, CT, PET, MRI or laparotomy~* Karnofsky index \>= 70~* stomach and duodenum not infiltrated by tumour~* given informed consent to study procedures~* Hb \> 9 g/dL, N\> 1500, PLT\> 100000~* creatininemia \< 1.5 mg/dL; bilirubinemia \< 1.5 times upper normal values; albumin \> 3 g/dL~* DPD normal activity~* contraception required and breast feeding not permitted~Exclusion Criteria:~* non resectable, locally advanced tumours~* insular cells tumour~* comorbidities excluding abdominal surgery and/or chemo- radiation therapy~* known metastasis~* DPD low activity~* inability to attend study procedures and follow ups~* pregnancy~* previous diagnosis of other tumour with more disadvantageous prognosis then the study object~* metallic biliary stent~* metallic prothesis or any other condition to prevent from target volume individuation and dose calculation~* clinical condition preventing from radiation therapy (i.e. infections in the irradiation area)~* medical and/or psychical condition preventing from radiation therapy~* past radiation therapy on abdomen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Preoperatory chemoradiation therapy with carbon ions (Type: EXPERIMENTAL): Chemoradiation followed by surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Efficacy of Corneal Cross Linking for the Treatment of Myopia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent~* Willingness to follow all instructions and comply with schedule for follow up visits~* Having myopia with manifest refraction spherical equivalent of -1.00 to -2.50 D, with cylindrical component pl to -0.75 D~* Social security insurance or equivalent~Exclusion Criteria:~* sensitivity to the use of the test article(s)~* hypersensitivity to local anesthesics~* Corneal pachymetry that is \< 480 microns~* Eyes with keratoconus~* Eyes which are aphakic or with corneal intacs~* Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example: History of corneal disease (e.g., herpes simplex, recurrent erosion syndrome, corneal dystrophy, refractive keratotomy etc.), clinically significant corneal scarring in the crosslinking treatment zone~* Pregnancy or lactation~* Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing~* Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment.~* Juridical protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Corneal cross linking (CXL) (Type: EXPERIMENTAL): Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* more or equal than 18 years old,~* patient with triple antihypertensive therapy (maximum tolerated dose) with a diuretic, except for anuric patients, and without modification treatment:~* in the last two months,~* expected in the next three months,~* renal transplanted patients with native kidneys followed for hypertension before transplant, and having a arterial systolic pressure ≥ 160 mmHg on the average of 3 measurements taken during the screening consultation and during at least one previous consultation OR~* chronic renal failure patient with dialysis and having a arterial systolic pressure ≥ 160 mmHg on the average of 3 measurements taken during the screening consultation and during at least one previous consultation~* patient affiliated to social security or similarly regime~* patient who signed the consent to participate in the study~No Inclusion Criteria:~* renal artery anatomy against-indicating the procedure including:~* 3 homolateral renal arteries~* kidney surgery including bypass surgery or renal artery reimplantation~* volume-dependent type of hypertension~* secondary hypertension (not included nephropathy)~* orthostatic hypotension associated with symptoms during the previous year~* medical history including:~  * acute coronary syndrome, unstable angina, stroke within 6 months preceding the period of inclusion,~ * surgery scheduled on the kidney, the renal arteries or the retroperitoneum during patient participation in the study period~ * chronic alcoholism~* anticoagulants or antiplatelet agents for which a therapeutic window can not be considered (except aspirin dose less than or equal to 160mg / day)~* contraindication to the realization of an MRI~* included in another trial assessing a medicament or a medical device or a surgical procedure~* protected person referred to in Articles L1121-5 to L1121-8 of the Code of Public Health

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Renal sympathicolysis (Type: EXPERIMENTAL): The patient will have:~1. Ambulatory Blood Pressure Monitoring~2. Magnetic Resonance Angiography~3. Blood test~4. Renal sympathicolysis~5. Ambulatory Blood Pressure Monitoring~6. Magnetic Resonance Angiography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues